FutureGen is a biopharmaceutical corporation that specializes in creating and commercializing groundbreaking biologics in the fields of immunology and oncology. The company employs a state-of-the-art screening platform known as STEP (Structure-based Targeted Evolution Platform), which combines various technologies to swiftly identify and produce optimal antibodies. With expertise in drug development, clinical trials, CMC, and quality control, FutureGen has established itself as a prominent player in the industry.

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Monoclonal antibody

Bispecific antibody

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	13
Immune System Diseases	4
Hemic and Lymphatic Diseases	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Monoclonal antibody	7
Bispecific antibody	5
Antibody drug conjugate (ADC)	3
Trispecific antibody	1

Top 5 Target	Count

PDL1 x TIGIT(Programmed death-ligand 1 x T cell immunoglobulin and ITIM domains)	2
CLDN18.2(Claudin 18.2)	1
TIGIT(T cell immunoglobulin and ITIM domains)	1
CD112R x TIGIT(Transmembrane protein PVRIG x T cell immunoglobulin and ITIM domains)	1
CD40 x PDL1(Tumor necrosis factor receptor superfamily member 5 x Programmed death-ligand 1)	1

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 01 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1 Clinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

M108 ( CLDN18.2 )	CLDN18.2 positive stomach adenocarcinoma More	Phase 3
B-901 ( CD40 x PDL1 )	Solid tumor More	Phase 1
M-137	Fibrosis More	Preclinical
B-267 ( TIGIT )	Solid tumor More	Preclinical
FG-B902 ( CD112R x TIGIT )	Solid tumor More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis